Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Non-Deal Roadshow (June 2024)
33 slides from Amoeba Sa's roadshow presentation, June 2024
Slide 1: 2024 Commercial Presentation
2024 | Commercial Presentation 1
Slide 2: Agenda
01 02 03 04 05 05 06 ABOUT COSMETICS OTHER PRODUCTION FINANCE CONCLUSION APPLICATIONS Introduction Recent innovations Biocontrol Capacity Financing Priorities Governance In vitro testing & Biocide development Shareholding Amoeba clinical trial Other applications Road to market 2
Slide 3: About
ABOUT ~~ amoéba
Slide 4: French greentech: target to break even in 2026-2027
About FRENCH GREENTECH: TARGET TO BREAK EVEN IN 2026-2027 Founded in 2010 in Chassieu, Amoéba is a French greentech listed on Euronext Growth since 2015. Amoéba is specialized in developing natural microbiological solutions based on the patented use of amoebas. 25 M€ 39 1 19 Patents, with 9 Invested
Slide 5: Executive Committee
About EXECUTIVE COMMITTEE A new dynamic driven by a united team with solid experience in the health sector in international environments Jean-François Doucet Jean-Baptiste Eberst Sandrine Troussieux Hervé Testeil Chief Executive Officer Regulatory Affairs Scientific Director Industrial Director Doct
Slide 6: Board of Directors
About BOARD OF DIRECTORS Benoit Villers Chairman REALIGNED TEAM COMMITTED TO THE SUCCESS Executive and Director OF AMOEBA’S NEW STRATEGY Nice & Green Business management and commercial strategy Valérie Lorentz-Poinsot Jean-Marc Petat Quentin Hua Director and CEO Laboratoires Former Executive Directo
Slide 7: What is an amoeba?
About WHAT IS AN AMOEBA? • Amoeba: natural single-celled microorganism present in all compartments of the environment, especially in wet environments, including the human body. Thousands of amoebas have been identified • They are still relatively unexplored • Our amoeba: Willaertia C2C Maky • Use in
Slide 8: Unique microorganism and know-how
About UNIQUE MICROORGANISM AND KNOW-HOW Amoéba stands out through its unique world- Specific features of the amoeba renowned expertise: a technological platform for the used industrial cultivation of amoebas with patented applications W. C2C Maky is biosourced, initially in the thermal waters of Aix
Slide 9: One microorganism, several applications
About ONE MICROORGANISM, SEVERAL APPLICATIONS ONE MICROORGANISM, SEVERAL APPLICATIONS Pre commercial Pre commercial Biocontrol Cosmetics Development Biocide Crop treatment Cosmetics ingredients platform Closed loop water High-potential markets treatment Natural crop protection Skin ingredient with p
Slide 10: Cosmetics, a new era for Amoeba
2 COSMETICS, A NEW ERA FOR AMOEBA 10
Slide 11: A recent and very promising innovation
Application - Cosmetics A RECENT AND VERY PROMISING INNOVATION Access to a very strong value-added market • Recent innovation, but various tests already serving as proof of concept, and INCI registration (International Nomenclature of Cosmetics Ingredients) enabling commercialization to be launched
Slide 12: Recent and very promising innovation
Application - Cosmetics RECENT AND VERY PROMISING INNOVATION October 2023: results announced for the first in vitro study conducted SCIENTIFIC FINDINGS by Labskincreations* on 3D skin and BioTk*, supplemented by studies conducted by PKDerm*. • Organic, natural and unique cosmetic ingredient • Very s
Slide 13: Anti-aging and anti-UV effect - in vitro
Application - Cosmetics ANTI-AGING AND ANTI-UV EFFECT - IN-VITRO Epidermis DE junction Hyaluronic Acid - Dermis ANTI-AGING EFFECT: Ki67: epidermis renewal marker COL VII: cohesion between the dermis and epidermis Hyaluronic Acid: essential for hydration, present in the dermis Measurement of key mark
Slide 14: Effects confirmed with a clinical trial
Application - Cosmetics EFFECTS CONFIRMED WITH A CLINICAL TRIAL May 2024: results of the first clinical trial carried out under the strictest conditions • 30 individuals covering half of the face (n=60) • Comparison against placebo - simple formulation to minimize its impact on the trial results - w
Slide 15: Road to market
Application - Cosmetics ROAD TO MARKET Our offering Timing Today, one active ingredient, tomorrow, several active March 2024: INCI ingredients or patented combinations of active ingredients Securing our cosmetic ingredient’s registration on the list of INCI + reduced dependence on a particular clien
Slide 16: Other applications
S OTHER APPLICATIONS ~~ amoéba
Slide 17: Biocontrol: a fast growing market
Application - Biocontrol BIOCONTROL: A FAST GROWING MARKET Europe supporting biocontrol A 10% growth market in Europe 2020 Farm to Fork strategy objectives which France The European market is valued at €1.6 billion in 2023, aligned itself with in May 2024: i.e. 10% of the total plant protection mark
Slide 18: Axpera: a real solution for the transition from chemical to organic production
Application - Biocontrol AXPERA: A REAL SOLUTION FOR THE TRANSITION FROM CHEMICAL TO ORGANIC PRODUCTION Positive impact on agriculture Approved by technical experts 600+ tests carried out in 19 countries, Unrivaled performance level for a biocontrol product including 200 with partners (technical and
Slide 19: Ideal solution for reducing copper use
Application - Biocontrol IDEAL SOLUTION FOR REDUCING COPPER USE • Copper is widely used to combat mildew, but this involves an issue with the metal accumulating in the soil and its use is expected to be scaled back by the regulatory framework in 2025 • With a campaign of 6 treatments, 4 doses of Axp
Slide 20: Regulatory timeline
Application - Biocontrol REGULATORY TIMELINE Very close to approval, with the riskiest steps successfully completed S2- S1-2022 S1-2023 S2-2023 S1-2024 S2-2024 S1-2025 S2-2025 2022 European Recommendation Union of active substance Peer-review by Peer-review by EFSA Peer-review by EFSA & EFSA conclus
Slide 21: Road to market: a new approach to Amoeba's sales strategy
Application - Biocontrol ROAD TO MARKET: A NEW APPROACH TO AMOEBA'S SALES STRATEGY Until 2023, a complicated commercial approach: • Priority focus on segments with strong margins • Search for a commercial partner for distribution and a • Discussions underway with partners able to develop capital par
Slide 22: Biocide
Application - Biocide BIOCIDE First application developed by Amoéba First biological • Innovation patented and tested in real situations by major players such as biocide approved Sanofi, Aéroports de Paris (AdP) and ArcelorMittal. in the US for the • Proven efficacy on biofilms, outperforming tradit
Slide 23: Development platform
Application - Other applications DEVELOPMENT PLATFORM Our R&D laboratory is continuously looking for new strong Lysed ferment base value-added applications for the use of the living amoeba Wound healing, burns treatment, acne, anti-mold or lysed ferment. paints Future developments to be carried out
Slide 24: Production
L, PRODUCTION ~~ amoéba
Slide 25: Drive to increase capacity
Production DRIVE TO INCREASE CAPACITY 2024 2025/2026 2027 Later Existing line in Chassieu. Ramp-up in 3 phases in Priority to identify a Proposed facility to be Current capacity of 500kg of Chassieu. Gradual transition production and distribution looked into based on active substance per year from 0
Slide 26: Financing
5 FINANCING ~~ amoéba
Slide 27: Balance sheet
Financing BALANCE SHEET Bilans simplifiés en Keuros 31/12/2023 31/12/2022 31/12/2021 Normes IFRS audité audité audité Subordinated bond financing: 6-month Euribor rate + 600 pts 12 mois 12 mois 12 mois - 2023 cost of debt: 136 K€ TOTAL ACTIF 6 286 12 404 14 516 Actifs non courants 3 660 5 275 6 067
Slide 28: Proposed legal reorganization
Financing PROPOSED LEGAL REORGANIZATION Listed company: - R&D - Production AMOEBA S.A. - Support services Operating companies for Cosmetics Biocontrol each business line New organization in place Q4 2024, subject to board approval 28
Slide 29: Cash burn and shareholding
Financing CASH BURN AND SHAREHOLDING 2024 Shareholding structure OPEX Revenues Capacity investments 6.6 M€ - 0.5 M€ 2025 OPEX Revenues Capacity investments 30% 7.5 M€ - 6.5 M€ % 2026 OPEX Revenues Capacity investments 70% 8 M€ 3 M€ - 2027 Individual shareholders OPEX Revenues Capacity investments Ni
Slide 30: Conclusion
6 CONCLUSION ~~ amoéba
Slide 31: Priorities
Conclusion PRIORITIES ✓ Absolute and immediate focus on the road to market for cosmetics and biocontrol ✓ Generation of the first revenues and return on investment ✓ Search for industrial and commercial partners to accelerate go to market ✓ Search for financial partners interested in the biocontrol
Slide 32: @AmoebaNature amoeba-nature.com contact@amoeba-nature.com
@AmoebaNature amoeba-nature.com contact@amoeba-nature.com 32
Slide 33: Disclaimer
DISCLAIMER References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question and answer session following that oral presentation and any further information that may b